A recent study shows the OCRDs, especially those that are more body-focused, have the potential to emerge or worsen during pregnancy and the postpartum, leading to high levels of comorbid depression and functional impairment.
Moving Backwards? Why Doesn’t the Canadian Task Force on Preventive Health Care Recommend Standardized Screening for Perinatal Depression?
This task force does not recommend universal, instrument-based screening for perinatal depression because we lack clear evidence that screening improves outcomes.
Women with postpartum psychosis are at risk for recurrent illness, but we have limited data regarding risk factors for recurrence.
Interested in telling your story or know of others who wish to share their PPD journey? We seek those who may be interested in participating in the documentary in some capacity.
Intravenous ketamine at delivery reduced risk for postpartum depression; however, only in women at high risk for PPD.
Lower risk for self-harm was observed during pregnancy, except in women aged 15 to 19 years.
Intranasal oxytocin improves mood in postpartum women but has no impact on mood in women with more severe depressive symptoms.
About 60% of women with mood disorders experience premenstrual exacerbation or PME of their mood during the premenstrual phase of their cycle.
The Women's Mental Health Program at the University of Arkansas for Medical Sciences has observed a fourfold increase in postpartum psychosis in the pandemic.
Sage Therapeutics and Biogen Announce Plans to Submit a New Drug Application for Zuranolone to the FDA in 2022
The FDA will review zuranolone for the treatment of depression in the first half of 2022.